Multivalency Beats Complexity: A Study on the Cell Uptake of Carbohydrate Functionalized Nanocarriers to Dendritic Cells by Krumb, M. et al.
cells
Article
Multivalency Beats Complexity: A Study on the Cell
Uptake of Carbohydrate Functionalized Nanocarriers
to Dendritic Cells
Matthias Krumb 1,† , Marie-Luise Frey 2,†, Jens Langhanki 1, Robert Forster 1,
Danuta Kowalczyk 1, Volker Mailänder 2,3, Katharina Landfester 2,* and Till Opatz 1,*
1 Department of Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10–14,
55128 Mainz, Germany; krumb@uni-mainz.de (M.K.); jens-gerald.langhanki@basf.com (J.L.);
rforster@students.uni-mainz.de (R.F.); kowalda@uni-mainz.de (D.K.)
2 Max Planck Institute for Polymer Research (MPIP), Ackermannweg 10, 55128 Mainz, Germany;
frey@mpip-mainz.mpg.de (M.-L.F.); volker.mailaender@unimedizin-mainz.de (V.M.)
3 Dermatology Clinic, University Medical Center of the Johannes Gutenberg-University Mainz,
Langenbeckstr. 1, 55131 Mainz, Germany
* Correspondence: landfester@mpip-mainz.mpg.de (K.L.); opatz@uni-mainz.de (T.O.)
† These authors contributed equally to this work.
Received: 1 August 2020; Accepted: 9 September 2020; Published: 12 September 2020


Abstract: Herein, we report the synthesis of carbohydrate and glycodendron structures for dendritic
cell targeting, which were subsequently bound to hydroxyethyl starch (HES) nanocapsules prepared by
the inverse miniemulsion technique. The uptake of the carbohydrate-functionalized HES nanocapsules
into immature human dendritic cells (hDCs) revealed a strong dependence on the used carbohydrate.
A multivalent mannose-terminated dendron was found to be far superior in uptake compared to the
structurally more complex oligosaccharides used.
Keywords: carbohydrates; glycodendrons; dendritic cells; nanocapsules; cell targeting
1. Introduction
The synthesis and characterization of nanocarrier systems is an emerging discipline in modern
nanomedicine, where bioavailability, biodegradability, adequate release, efficient coupling of the drug
to the nanocarrier (e.g., by encapsulation) and also targeted delivery of the drug to its destination play
key roles and need to be finely tuned [1]. In particular, targeted drug delivery to certain cell types is a
highly desirable strategy and the targeting of dendritic cells (DCs) in terms of tumor immunotherapy
has gained wide attention in recent years [2]. Due to their ability to activate the adaptive immune
response, DCs play a key role in delivering information to the immune system. Therefore, they can
serve as important mediators in nanomedicine to deliver antigens upon targeting and cell uptake
of antigen-loaded nanocarriers [3]. The targeting of DCs is possible through their surface receptor
dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), which is
known to bind carbohydrate recognition structures through a C-terminal carbohydrate recognition
domain (CRD) [4–6]. The DC-SIGN receptor is a tetramer that carries four of these CRD domains and
can therefore theoretically bind up to four ligands simultaneously [7]. As a consequence, DC-SIGN
specifically and strongly binds high-mannose-type oligosaccharides, in which mannose units are
presented in a multivalent manner. It can therefore be deduced that multivalency might be a universal
promising strategy to maximize the carbohydrate lectin interactions in terms of DC-SIGN targeting
with nanocarriers.
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In general, multivalency is a key strategy within nature to achieve strong but yet reversible
interactions [8]. Nature uses multivalency in key biological processes such as cell–cell-communication
or the recognition of pathogens, like viruses, on the cell surface to just name a few examples [9].
It appears particularly remarkable that nature has orchestrated such highly complex biological processes
which are traced back to rather weak single physicochemical interactions. For example, the binding of
a single carbohydrate to a lectin is often weak, while simultaneous binding of many, often branched
and complex oligosaccharides to lectins creates strong signals [10]. The binding pocket of lectins is
located on the surface of the protein, where the binding of carbohydrates results from the complexation
of bound metal ions or amino acid residues. As a result, this binding does not occur deep inside the
protein, which makes it difficult to achieve a strong binding in tight, deep pockets. [11,12]. However,
since biological processes run in a highly orchestrated manner, the minor influence of single signals in
comparison to the major influence of multivalent signals makes sense [13,14]. Another explanation is
that cell surface receptors seldom operate alone but rather form clusters at the cell surface to permit
signal transduction [14]. A multivalent ligand could therefore help to achieve such a clustering process
at the cell surface. As previously mentioned, some cell surface receptors like DC-SIGN exhibit multiple
CRDs, in which a multivalent ligand could occupy more than one pocket to amplify the binding
signal [12]. Secondly, a statistical rebinding of a single ligand is increasingly probable if a multivalent
ligand is present, which increases the effective concentration against the receptor [15]. Over the years,
the synthesis of glycodendrimers and dendrons has greatly evolved and a variety of platforms were
produced that serve as a basis for multivalent glyco-targeting [16–18]. These systems become more
useful if they are applied for the surface functionalization of nanocarriers, which can be used to
protect and safely transport therapeutics to specific sites of action, such as specific cell populations.
In particular, biopolymers such as hydroxyethyl starch (HES) are particularly suitable candidates
for transport because they are biocompatible, degradable and many of them are already medically
approved [19].
The goal of this project was therefore to synthesize a series of carbohydrate-based ligands suitable
for DC-SIGN targeting and to compare them to a multivalent ligand in form of a glycodendron.
With this series in hand, we analyzed whether the carbohydrate lectin binding is enhanced by a
multivalent ligand, thus enabling effective targeting. The targeting ability of these ligands to DCs was
subsequently explored through conjugation to a carrier system, where HES nanocapsules were chosen
as an ideal carrier platform for the latter since they are produced from medically approved material,
but also shown to be robust and biocompatible in earlier studies [19–21]. Afterwards, the targeting
ability of the carbohydrate HES conjugates was explored in cell uptake experiments and confirmed
through follow up blocking studies with antibodies.
2. Materials and Methods
2.1. Solvents and Reagents
Unless stated otherwise, all chemicals were obtained from commercial suppliers such as Sigma
Aldrich (St. Louis, MO, USA), Thermo Fisher Scientific (Waltham, MS, USA), TCI (Tokyo, Japan),
ABCR (Karlsruhe, Germany) and used without purification. Deuterated solvents were purchased
from Deutero GmbH (Kastellaun, Germany). Anhydrous acetonitrile and dichloromethane were
distilled from calcium hydride under nitrogen atmosphere. Extra dry dimethylformamide (DMF)
was purchased from Acros Organics (AcroSeal® glass bottle, part of Thermo Fisher, Waltham, MS,
USA). The eluents for column chromatography (cyclohexane (cHex) and ethyl acetate (EtOAc)) were
purchased in technical grade and distilled prior to use. Chloroform-d was stored over alumina
(Brockmann activity I). Ampuwa® water and hydroxyethyl starch (HES, Mw: 200 kDa, 0.5, 3%),
dissolved in an isotonic sodium chloride solution, was obtained from Fresenius Kabi (Bad Homburg,
Germany) DBCO-PEG4-NHS ester was purchased from Jena Bioscience GmbH (Jena, Germany).
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The block copolymer poly((ethylene-co-butylene)-b-(ethylene oxide)) P(E/B)-b-EO) used as surfactant
was synthesized according to previously published procedures from Schlaad et al. [22].
2.2. Reaction Conditions
All reactions involving air- or moisture-sensitive reagents or intermediates were performed under
an inert atmosphere of argon in glassware that was oven dried using standard Schlenk techniques.
Reaction temperatures referred to the temperature of the particular cooling/heating bath.
2.3. Chromatography
Chromatographic purification of products was performed using flash column chromatography
of the indicated solvent system on silica gel (35–70 µm, Acros Organics unless otherwise noted.
Alternatively, purification was performed on an IsoleraTM Flash Purification System, Biotage, Uppsala,
Sweden) with an integrated diode array detector.
Thin-layer chromatography (TLC) was carried out on silica plates (TLC Silica 60 F254 by Merck,
Darmstadt, Germany). UV active compounds were visualized using UV light (λ = 254 nm). Oxidation
labile compounds were visualized by immersion in a solution of cerium(IV) sulfate (1.00 g) and
phosphomolybdic acid (2.50 g) in water (95.0 mL) and concentrated sulfuric acid (4.00 mL) followed by
heating. Alternatively, the TLC plates were immersed in a solution of m-methoxyphenol (0.10 mL) in
ethanol (95.00 mL) and sulfuric acid (2.00 mL) followed by heating to stain saccharides specifically.
Analytical HPLC analysis was performed on an Agilent Technologies (Santa Clara, CA, USA)
1260 Infinity II system equipped with a binary pump and a diode array detector. An ACE (Aberdeen,
UK) C18 PFP column (150 × 4.6 mm, 3 µm, 40 ◦C) with a flow rate of 1 mL/min was used.
Preparative reverse phase separation was carried out on a Smartline HPLC system (Knauer, Berlin,
Germany) with mixtures of acetonitrile (HPLC grade) and water (HPLC grade) as eluents on an ACE 5
C18 PFP 150 × 30 mm column, at a flow rate of 37.5 mL/min. The eluents were degassed prior to use
by means of ultrasonication for 30 min. Two Smartline K 1800 pumps (pump head size: 100 mL each,
high pressure gradient; Knauer) and an S 2600 diode array detector (Knauer) were used.
2.4. NMR Spectra
NMR spectra were recorded on a Bruker (Billerica, MA, USA) Avance-III HD (1H-NMR:
300 MHz, 13C-NMR: 75.5 MHz), a Bruker Avance-II (1H-NMR: 400 MHz, 13C-NMR: 100.6 MHz)
or a Bruker Avance-III (1H-NMR: 600 MHz, 13C-NMR: 151.1 MHz) spectrometer. Chemical shifts are
referenced to residual solvent signals (CDCl3: 7.26 ppm and 77.16 ppm, DMSO-d6: 2.50 ppm and
39.52 ppm for 1H-NMR and 13C-NMR respectively) and reported in parts per million (ppm) relative
to tetramethylsilane (TMS). Multiplicities of NMR signals are abbreviated as follows: br = broad,
s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet and combinations thereof, app = apparent.
The spectrometer was calibrated using α,α,α-trifluorotoluene in CDCl3 (−63.9 ppm).
2.5. Infrared Spectra
Infrared (IR-) spectra were recorded on a FTIR-spectrometer (Bruker, Billerica, MA, USA; Tensor 27)
equipped with a diamond ATR unit and are reported in terms of frequency of absorption (cm−1).
2.6. UV-Vis Spectra
UV-Vis spectra were recorded on an Evolution 201 UV-Visible Spectrophotometer from
Thermo Scientific.
2.7. Mass Spectra
Electron spray ionization (ESI) mass spectra were recorded on a 1200-series HPLC-system
or a 1260-series Infinity II HPLC-system (Agilent-Technologies) with binary pump and integrated
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diode array detector coupled to a LC/MSD-Trap-XTC-mass spectrometer (Agilent-Technologies) or a
LC/MSD Infinitylab LC/MSD (G6125B LC/MSD). High-resolution mass spectra were recorded on a
Micromass-Q-TOF-Ultima-3-mass spectrometer (Waters, Milford, MA, USA) with LockSpray-interface
and a suitable external calibrant. The reported high-resolution masses refer to the neutral molecules
since the mass of the single electron (which is removed to form the cationic species) was considered
during calibration. LIFDI mass spectra were recorded on a double focusing LIFDI sector field mass
spectrometer (Thermo Fischer DFS).
2.8. Melting Points
Melting points were determined in open capillary tubes using a Krüss-Optronic (Hamburg,
Germany) KSP 1 N thermoelectric melting point meter.
2.9. Optical Rotations
Optical rotation of chiral compounds was determined on a Perkin-Elmer (Waltham, MS, USA)
241 MC polarimeter. Compounds were dissolved in chloroform or methanol. Concentrations are given
in g/100 mL.
2.10. Sonication
For ultrasonication a Branson Sonifier W-450-Digital (Branson Ultrasonics Corporation, Danbury,
CT, USA) was used with a 1/2′ tip. For ultrasonication in a sonication bath, a Bandelin Sonorex RK52H
from Bandelin electronic (Berlin, Germany) was used.
2.11. Light Scattering and Zeta Potential
DLS measurements have been performed in technical triplicates on a Malvern Zetasizer Nano S90
(Malvern Panalytical GmbH, Kassel, Germany) at an angle of 90◦.
Zeta potential has been measured in technical triplicates on a Malvern Zetasizer NanoZ (Malvern
Panalytical GmbH). Nanocapsule dispersions were diluted in a potassium chloride solution (1 mM,
25 ◦C, pH 6.8) prior to measurement.
2.12. Transmission Electron Microscopy (TEM)
TEM was performed by placing a drop of diluted nanocapsule dispersion onto a 300-mesh
carbon-coated copper grid and drying under ambient conditions. TEM measurements were operated
on a Jeol 1400 transmission electron microscope from Jeol GmbH (Freising, Germany).
2.13. Fluorescence Intensity Measurements
Fluorescence intensity measurements were operated in 96-well plates on the Infinite M1000 plate
reader from Tecan (Männedorf, Switzerland). Measurements were performed with two dilutions in
duplicates each.
2.14. Flow Cytometry and Confocal Laser Scanning Microscopy
For flow cytometry analysis, cells were detached and measurements were performed on an Attune
NxT flow cytometer (Thermo Fisher). Confocal laser scanning microscopy was performed on a Zeiss
LSM 710 NLO from Carl Zeiss Microscopy GmbH (Jena, Germany).
2.15. Experimental Procedures and Compound Characterization
Detailed synthetic procedures are given within the Supplementary Material.
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2.16. Generation of Immature or Mature Dendritic Cells
All experiments were performed in compliance with the relevant laws and institutional guidelines.
The institutional ethics committee approved the study (Landesärztekammer Rheinland-Pfalz, 837.439.12
(8540-F), approved on 02.01.2017). Written informed consent was obtained for any experimentation
we carried out when using samples from human subjects. As mentioned above, the studies were
conducted in full accordance with the Declaration of Helsinki.
Dendritic cells were generated from monocytes using plastic adherence. PBMC were seeded
at a density of 5 × 106 cells per well of a 24-well plate. Cells were allowed to adhere in
a humidified environment at 37 ◦C with 5% CO2 for 1 h in 1 mL per well of DC-medium
(RMPI with 2% heat-inactivated pooled human serum (HS), 100 U/mL penicillin (Gibco™, Fisher
Scientific GmbH, Schwerte, Germany), and 100 mg/mL streptomycin (Gibco). By multiple washing
with phosphate-buffered saline (PBS, Invitrogen™, Fisher Scientific GmbH, Schwerte, Germany),
non-adhering cells were removed. Monocytes were kept in DC-medium containing 100 ng/mL
granulocyte-macrophage-colony stimulating factor (GM-CSF, PeproTech, Cranbury, NJ, USA) and
100 ng/mL interleukin-4 (IL-4, PeproTech, Cranbury, NJ, USA) at 37 ◦C/5% CO2 for two days. On day 3,
immature dendritic cells (iDC) were harvested by washing once with PBS and incubating cells with
PBS/EDTA (2 mM) at 4 ◦C for 10 min. Prior to experiments, cells were examined for the expression of
CD11c and CD86 by employing flow cytometry.
2.17. Loading of DC with Nanocapsules
1 × 105 DCs were incubated with NC at 37 ◦C/5% CO2 in DC medium supplemented with
1600 U/mL GM-CSF and 500 U/mL IL-4. Two different nanocapsule concentrations (37.5 or 75 µg/mL)
were analyzed after an incubation period of 2 h. Afterwards, cells were collected using multiple
washing steps with cold PBS. The nanocapsule containing supernatant was removed by centrifugation
for 5 min at 470 g.
2.18. Flow Cytometry Analysis of NC-Loaded DC
Pelleted DCs were stained with CD11c-FITC (Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach,
Germany), CD45-APC-Cy7 (BD Biosciences, San Jose, CA, USA) and CD45-V450 (BD Biosciences,
San Jose, CA, USA). Cells were allowed to incubate with the various antibodies for 15 min at 4 ◦C. After a
washing step with PBS/0.1 % BSA, the cells were centrifuged and resuspended in 300 µL PBS/0.1%
BSA. NC uptake by DC was detected using an Attune NxT flow cytometer (Thermo Fisher, Waltham,
MS, USA), selecting the cells with an FSC/SSC plot, thereby excluding cell debris. Fluorescence of the
NC dye sulforhodamine (SR101) was detected using a 586/15 nm bandpass filter with excitation by a
100 mW/561 nm laser.
2.19. Statistical Methods
For the cell uptake experiments, the program GraphPad Prism 5 (GraphPad Software, San Diego,
CA, USA) was used. Data analysis was conducted using two-way analysis of variance (ANOVA).
The cell uptake experiments were performed in duplicates. Two different nanocapsule batches were
used, of which one batch is described in Figures 3 and 4 of the main manuscript and the second one in
Figure S32 (Supplementary Material).
3. Results
It is known that DCs recognize different carbohydrates and complex glycan structures
through their DC-SIGN-receptor [23,24]. A key study by Holla and Skerra revealed that simple
mannose-units, and especially branched oligomannosidic structures, in particular a trimannose
structure (3,6-di-(α-d-mannopyranosyl)-α-d-mannopyranose) as well as fucose-containing saccharides,
in particular a disaccharide (3-(β-l-fucopyranosyl)-2-acetamido-2-deoxy-β-d-glucopyranose),
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are recognized by DC-SIGN [25]. Based on these observations, we selected four different potential
ligands for DC-SIGN that carry a poly(ethylene glycol) (PEG)-based, azide-terminated linker to enable
covalent binding through azide-alkyne click reactions to nanocarriers as the target structures for total
synthesis (Figure 1) A simple d-mannose monosaccharide 1 and the mentioned trimannose structure 2,
which were available from earlier studies [4,26,27], as well as a fucose containing disaccharide 3 and a
mannose-terminated glycodendron 4, were chosen as potential ligands.Cells 2020, 9, x 6 of 13 
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Figure 1. Chemical structures of selected carbohydrate ligands for receptor dendritic cell-specific
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) targeting and corresponding
symbol nomenclature adopted by the consortium for functional glycomics [28].
The synthesis of the fucose disaccharide 3 started from N-acetylglucosamine (5), which was
deprotonated at the most acidic 1-OH position and then was β-selectively alkylated with progargyl
bromide in 52% yield (Scheme 1, top) [29]. The 4- and 6-positions were then benzylidene-protected
in 59% yield through reaction with benzaldehyde dimethyl acetal to give derivative 6 over two
steps. Next, l-fucose (7) was peracetylated in 99% yield and then transformed into the glycosyl
bromide 8 in 89% using HBr in acetic acid. Building blocks 6 and 8 were then combined under
Helferich conditions using Hg(CN)2 in toluene and MeNO2 to furnish the disaccharide in 86%
yield [30]. This was followed by the introduction of the azide PEG-linker 9 in 86% yield using
conditions for the CuAAC-reaction (copper-catalyzed alkyne-azide cycloadditon) with CuBr and
PMDTA (N,N,N’,N”,N”-pentamethyldiethylenetriamine) as the ligand [31]. Finally, the benzylidene
acetal was removed using TFA followed by global deprotection under Zemplén conditions to furnish
the desired disaccharide 3 over six linear steps with 11% total yield.
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Scheme 1. Synthesis of the disaccharide 3 from N-acetylglucosamine (5) and l-fucose (7) over eight
steps with (top) and synthesis of the mannose glycodendron 4 from Tris (10) over seven steps (bottom).
After successful synthesis of disaccharide 3, the synthesis of the desired mannose glycodendron
4 was addressed. The dendron core was constructed starting from Tris (10, tris(hydroxymethyl)
aminomethane), which was polyalkylated using tert-butyl acrylate (11) in 25% yield. Then, the amino
group was protected in 50% yield using o-nitrobenzyl chloroformate, which was synthesized from
o-nitrobenzyl alcohol upon reaction with triphosgene in situ (see the SI for more details). The ester
moieties were cleaved using TFA and then functionalized with amine-azide linker 13 to give the
dendron core 14 under standard amide coupling conditions in quantitative yield [32]. Mannose alkyne
15, which was synthesized according to a previous report [26], was coupled to the dendron core 14 using
the previously mentioned CuAAC conditions in 75% yield. The tertiary amine in the dendron core was
then deprotected using a photochemical cleavage of the o-nitrobenzyl moiety upon irradiation with
UV-A light [33]. Previous efforts with other protecting groups suffered from either poor reproducibility
or poor yield upon deprotection, which underlines the mildness and efficiency of this light-induced
protecting group cleavage. The obtained amine was then functionalized with another PEG-linker 16
in 41% yield followed by global deprotection to furnish the desired glycodendron 4 over eight linear
steps in 4% overall yield.
After the synthesis of the DC-SIGN ligands had been accomplished, hydroxyethyl starch (HES)
nanocapsules were prepared through interfacial crosslinking of toluene diisocyanate (TDI) with HES
in inverse miniemulsion [23,34–36]. Isocyanate groups of TDI reacted in a polyaddition reaction
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with hydroxyl groups of HES, resulting in the formation of a polyurethane shell [37]. We obtained
nanocapsules with a relative diameter of 250 nm in cyclohexane. High batch-to-batch reproducibility
was ensured. For further modification and biological testing, the nanocapsules were redispersed in
aqueous sodium dodecyl sulfate (SDS) solution. The hydrodynamic diameter of the nanocapsules in
aqueous solution decreased to approximately 200 nm (Figure 2A). Furthermore, TEM micrographs
proved the core-shell morphology of the obtained nanocapsules in cyclohexane (Figure 2B, left) as well
as in aqueous medium (Figure 2B, right).
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Figure 2. (A) Average size distribution of four hydroxyethyl starch (HES) nanocapsule batches in
cyclohexane and in water measured at an angle of 90◦. (B) TEM micrograph of HES nanocapsules in
cyclohexane (left) and in water (right). (C) Quantification of free dibenzocycloocytne (DBCO) groups
and DBCO groups clicked to functionalized carbohydrates per mL dispersion by a fluorescent assay.
During redispersion of the nanocapsules in water, residual isocyanate groups hydrolyze to amino
groups, which were then reacted with DBCO-PEG4-NHS ester. The so-attached dibenzocyclooctyne
(DBCO)-groups were exploited for copper-free click reaction with the synthesized carbohydrate ligands
1–4. Thus, a defined surface modification with DBCO groups can be achieved in order to covalently
bind as many carbohydrate molecules as possible. This is important because it is known that single
carbohydrates show rather low influence on the immune system, while multivalent presentation of
carbohydrates exhibits strong immunological properties, as mentioned in the introduction [10,11].
For quantification of DBCO groups on the nanocapsules, a fluorescent assay was used and the average
DBCO quantity was found to be 1.38 × 1017 DBCO groups per mL dispersion after coupling the
DBCO-PEG4-NHS ester to the nanocapsules (10 mg nanocapsules per mL) [36]. Then, we added a
three-fold molar excess of azide-containing carbohydrates with respect to previously detected DBCO
groups to the DBCO-functionalized nanocapsules. After three days, the remaining DBCO groups were
quantified (Figure 2C). We determined 20% of the initial DBCO groups. The decrease in the DBCO
can be attributed to the reaction of the azide, but additionally to the chemical sensitivity of the DBCO
molecule to other nucleophiles [37]. As a control, pure DBCO capsules showed a 36% decrease over
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time. Therefore, around 42% of the DBCO groups are coupled to carbohydrates. This is independent
of the carbohydrate added.
The relative size of the nanocapsules with functionalization and the surface charge is shown in
Table 1. The surface modification of the nanocapsules caused an increase in the hydrodynamic diameter
of the capsule. This is particularly noticeable with the bulky dendron. All samples, after coupling,
still showed a negative ζ-potential.
Table 1. Physicochemical properties of carbohydrate-modified HES nanocapsules. Average diameters
were determined at a scattering angle of 90◦.
Sample Average Diameter/nm ζ-Potential/mV
HES-DBCO 289 ± 26 −7.9 ± 6.8
HES-DBCO-Mannose 418 ± 105 −14.9 ± 4.1
HES-DBCO-Disaccharide 392 ± 41 −11.9 ± 3.2
HES-DBCO-Trimannose 514 ± 135 −10.1 ± 6.0
HES-DBCO-Dendron-Mannose 544 ± 54 −13.8 ± 1.1
After successful binding of the carbohydrates to the nanocapsules, cell uptake experiments
were performed. Therefore, human dendritic cells (hDCs) were incubated with DBCO-modified
HES nanocapsules (DBCO), with HES-DBCO nanocapsules surface modified with four different
carbohydrates (mannose 1, disaccharide 2, trimannose 3 and dendron-mannose 4) and with pure cell
medium as negative control (NC).
All nanocapsules were fluorescently labelled with the dye sulforhodamine. After incubation
and washing, flow cytometry experiments were performed. The uptake behavior of the differently
functionalized nanocapsules into hDCs is shown for the different experimental setups (see Figure 3).
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Figure 3. Uptake and blocking experiments of HES nanocapsules, decorated with carbohydrates into
human dendritic cells (hDCs) in three different experimental setups. The experiments were performed
in duplicates using ANOVA for data evaluation with a p-value = 0.006 (A), p-value < 0.0001 (B) and
p-value < 0.0001 (C).
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Next, we performed surface expression control of the hDCs and an isotype control (Figure 4).
hDCs were incubated with specific antibodies against CD206, CD209 and CD207 (langerin receptor),
excess antibody was washed off, and the cells were analyzed by flow cytometry.
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amount of residual DBCO was found on the different samples, independent of the structure of he
added c rbohydrat (Figure 3 ). It is ass med that the size and th steric natur of the respe iv
carbohy rate h s a significant influence on the binding o the nanocapsule. Therefore, w expect
that more of the respective carbohydr te is needed for a complete c verage of the nanocapsule with
mannose 1 than for coverage with dendron-ma nos 4. Despite th ass ciated molecul r excess of
mannose 1 n the n ocapsule, compared to r - a ose , the dendron-mannose decorated
nanocapsule appeared to be superior in uptake. Since the endron presents thre man ose units
p r dendron c upled to the nanocapsules, we also reduced th den ron density by a factor of thre
in order to have the sam mannose units per capsules as in th mono-mannose ca e (nanoc psules
with 1/3 of dendr n-mannose, d = 364 nm, ζ potential = 13 ± 2.6 mV). Independent of the amount
of the dendron-mannose, w found an i creased uptake into the cel s (see Supporting Information).
In the next step, we investigated if ind ed specific rec ptors mediate he c ll uptak . Therefore,
we first treated hDCs wi h antibod es against CD206 an CD209 to block the receptors. In this c s ,
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This is remarkable since it has been postulated in the literature that DCs recognize mannose units
through the mannose receptor CD206 [38], while branched oligomannosidic structures, in particular
trimannose 2, are internalized through DC-SIGN (CD209) [39,40]. However, the observation that
simple mono-mannose containing glycodendron 4 showed a strong decrease in uptake through
blocking of DC-SIGN contradicts this hypothesis and indicates that a multivalent binding of ligands
to DC-SIGN might play a bigger role than the (branched) structural complexity of oligosaccharides.
This finding underlines the initially mentioned importance of multivalent addressing of lectins
through carbohydrates.
The possibility of a receptor-mediated uptake mechanism was further investigated using a surface
expression control of the hDCs and an isotype control (Figure 4). We found that approximately 77% of
the hDCs population expressed CD206, 73% expressed CD209 and 98% expressed CD207 (see the SI for
more details). These results verify that a sufficient number of targeted receptors were present on the
surface of the hDCs. Furthermore, it was observed that when incubation of the cells was performed
with an unspecific IgG antibody (isotype control), the uptake of the different nanocapsules did not
differ from the non-blocked cells (Figure 4). The results demonstrate that there is a high probability for
receptor-mediated uptake of carbohydrate functionalized HES nanocapsules.
5. Conclusions
In summary, a series of mono- and oligosaccharide ligands for DC-SIGN were prepared and
covalently coupled to hydroxyethyl starch nanocapsules through copper-free click chemistry. The cell
uptake in human dendritic cells was investigated and revealed that a multivalent glycodendron is
superior in cell uptake to the 3,6-branched trimannose. Additionally, blocking experiments revealed
that mannose as well as the mannose glycodendron addressed DCs preferentially through CD209 rather
than through CD206, which underlines that the selectivity for branched mannose oligosaccharides,
might be traced back to multivalent presentation of saccharides in these structures rather than to
structural complexity. This initial discovery opens the way to the development of simpler multivalent
ligands rather than branched and structurally complex oligosaccharides to achieve effective DC-SIGN
targeting in future work.
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